Cancer early‑detection company Grail said it has agreed a private placement expected to raise roughly $325 million to support commercial expansion and reimbursement efforts. The financing includes participation from institutional and strategic investors and follows recent commercial and regulatory moves as the company scales Galleri and related services. Grail disclosed the transaction as part of a funding package intended to sustain operations into 2030, not including an earlier commitment from Samsung. Company statements indicate proceeds will be directed to market access, reimbursement engagement and working capital—areas that have challenged the multi‑cancer early detection field. For payers and diagnostics developers, the raise underscores continued investor appetite for high‑impact oncology diagnostics even as the sector presses for coverage and clinical‑utility data that can underpin broad adoption.